The short version
Direct-to-consumer (DTC) drug programs allow patients to purchase brand-name prescription medications straight from the manufacturer, usually at a fixed price and delivered by mail.
DTC and direct-to-patient (DTP) are closely related terms. DTC is the broader policy term used by regulators, while DTP is how most manufacturers brand their individual programs.
A 2025 executive order introduced the concept of "most-favored-nation" pricing, which would tie U.S. drug prices to what other high-income countries pay.
These programs offer real benefits: lower prices, no prior authorization, and home delivery. They also carry real risks: fragmented medical records, no deductible credit, and limited drug selection.
DirectRxGuide tracks every active DTC/DTP program in one place so you can compare options independently.
What does “direct-to-consumer” mean for prescription drugs?
In the traditional model, a patient gets a prescription from a doctor, takes it to a pharmacy, and either pays out of pocket or has their insurance cover part of the cost. The manufacturer sells the drug to a distributor, which sells it to the pharmacy, which sells it to you. Multiple middlemen take a cut along the way.
A direct-to-consumer (DTC) drug program removes most of those intermediaries. The manufacturer sets a fixed price, operates its own ordering platform, and ships medication directly to the patient through a contracted mail-order pharmacy. You still need a valid prescription from a licensed provider, but the purchasing and fulfillment happen outside the traditional pharmacy and insurance system.
The term “direct-to-consumer” has been used in health policy discussions and executive orders to describe this model at a broad level. It signals a structural change in how prescription drugs reach patients, not just a marketing label from any single company.
DTC vs. DTP: what is the difference?
You will see both “direct-to-consumer” (DTC) and “direct-to-patient” (DTP) used to describe these programs. The terms are often used interchangeably, but there is a useful distinction.
Direct-to-consumer (DTC)
This is the broader policy and regulatory term. It describes the overall model of manufacturers selling medications directly to end users, bypassing traditional pharmacy and insurance channels. Federal executive orders and health policy discussions typically use “direct-to-consumer” when referring to this approach.
Direct-to-patient (DTP)
This is the term most manufacturers use when branding their individual programs. LillyDirect, NovoCare, PfizerForAll, and other platforms are all DTP programs. The term emphasizes the patient relationship and the healthcare context, as opposed to the more general consumer framing.
In practice, DTC and DTP refer to the same thing: a manufacturer selling a prescription drug directly to the person who will take it, at a price set by the manufacturer, delivered to their door. DirectRxGuide uses “DTP” when referring to specific manufacturer platforms and “DTC” when discussing the broader policy landscape.
Most-favored-nation pricing: what it means for patients
In May 2025, an executive order directed the Department of Health and Human Services to explore pathways for Americans to purchase prescription drugs at “most-favored-nation” (MFN) prices. The concept is straightforward: the United States should not pay more for a drug than other wealthy nations do.
Under MFN pricing, the price of a drug sold in the U.S. would be benchmarked against the lowest price paid by a set of comparable high-income countries. If a brand-name drug costs $300 per month in the U.S. but only $80 in Canada or Germany, MFN pricing would aim to bring the American price closer to that $80 figure.
The executive order specifically pointed to DTC purchasing as one mechanism for making MFN prices available. The idea is that manufacturers could offer these lower prices directly to patients, bypassing the insurance and pharmacy layers that have historically inflated costs.
As of March 2026, MFN pricing has not been fully implemented. However, the policy direction has accelerated manufacturer interest in DTC/DTP platforms. Several major pharmaceutical companies have launched or expanded their direct programs in anticipation of this shift. Patients should understand that current DTP program prices are set by the manufacturers themselves and may or may not reflect true MFN benchmarks.
DTC/DTP platforms available today
As of March 2026, DirectRxGuide tracks 12 active manufacturer platforms offering direct-to-patient purchasing. Each platform covers a different set of brand-name medications.
| Platform | Manufacturer | Notable drugs |
|---|---|---|
| LillyDirect | Eli Lilly | Mounjaro, Zepbound, Humalog, Trulicity |
| NovoCare | Novo Nordisk | Ozempic, Wegovy, Rybelsus, Saxenda |
| PfizerForAll | Pfizer | Eliquis, Ibrance, Xeljanz |
| AZ Patient Direct | AstraZeneca | Farxiga, Symbicort, Breztri |
| AmgenNow | Amgen | Enbrel, Repatha, Otezla |
| BMS Patient Connect | Bristol-Myers Squibb | Eliquis (co-marketed), Opdivo |
| Boehringer Ingelheim Direct | Boehringer Ingelheim | Jardiance, Ofev, Pradaxa |
| Novartis Direct | Novartis | Entresto, Cosentyx, Kisqali |
| GSK for You | GSK | Trelegy, Nucala, Dovato |
| J&J Direct | Johnson & Johnson | Stelara, Tremfya, Xarelto |
| ELIQUIS DTP Program | Pfizer / BMS | Eliquis |
Program availability, pricing, and eligible medications change frequently. Use the DirectRxGuide Find My Options tool for the most current information.
Benefits of buying drugs direct from the manufacturer
DTC/DTP programs have grown rapidly because they solve real problems for patients. Here are the most significant advantages.
Lower out-of-pocket prices
Manufacturers set fixed prices that are often significantly lower than what you would pay at a pharmacy, especially if you are uninsured or have a high-deductible plan. Some programs offer medications at a fraction of the wholesale acquisition cost.
No prior authorization required
Because these programs operate outside of insurance, there is no prior authorization process. You do not need to wait for your insurance company to approve your medication before you can fill it. This eliminates one of the most common and frustrating delays in the current system.
Home delivery
Medications ship directly to your door through contracted mail-order pharmacies. There are no pharmacy lines, no waiting for refills, and no need to make a separate trip. Most programs ship to all 50 states.
Price transparency
DTP platforms display prices upfront before you commit. Unlike the traditional insurance model, where your actual out-of-pocket cost can be difficult to predict, you know exactly what you will pay before you order.
Access for uninsured patients
Patients without insurance often face the highest drug prices at traditional pharmacies. DTC programs offer a consistent, lower price regardless of insurance status, making brand-name medications accessible to people who might otherwise not be able to afford them.
Risks and trade-offs to understand
DTC drug programs are not without downsides. Before enrolling, consider the following.
Fragmented care and medication records
When you fill prescriptions at your local pharmacy, your pharmacist maintains a complete record of everything you are taking. They check for drug interactions, duplicate therapies, and dosing problems. When you order through a DTC program, the medication is dispensed by a separate mail-order pharmacy that does not share records with your local pharmacy or your doctor's office. This fragmentation means important safety checks can be missed. If you use a DTC program, make sure to tell both your doctor and your local pharmacist what you are taking.
Payments may not count toward your insurance deductible
Most DTC programs operate on a cash-pay basis. Your payment does not go through insurance, which means the money you spend typically will not count toward your annual deductible or out-of-pocket maximum. For patients who are close to meeting their deductible, using a DTC program could actually increase total annual spending by preventing them from reaching the threshold where insurance begins to cover more of their costs.
Limited to brand-name drugs
DTC programs focus exclusively on brand-name medications that are still under patent protection. If a generic version of your medication exists, the generic will almost always be cheaper at a local pharmacy. These programs are most valuable for patients who need brand-name drugs that do not yet have a generic equivalent.
The manufacturer sets the price
While DTC prices are often lower than traditional pharmacy prices, they are still set by the manufacturer. There is no independent negotiation or competitive bidding. Patients should compare the DTC price against other options, including insurance copays, discount programs, and pharmacy cash prices, before assuming the manufacturer price is the best available.
Not a substitute for comprehensive healthcare
Some DTC platforms include telehealth prescribing services. While convenient, these services connect you with a provider who may not know your full medical history. For patients with complex conditions or those taking multiple medications, working with a regular healthcare provider who understands your complete picture is safer and more appropriate.
DTC programs vs. traditional pharmacy: a side-by-side comparison
| DTC/DTP Program | Traditional Pharmacy | |
|---|---|---|
| Pricing | Fixed cash price from manufacturer | Varies by pharmacy and insurance plan |
| Insurance accepted | Usually no (cash-pay only) | Yes |
| Prior authorization | Not required | Often required for brand-name drugs |
| Delivery method | Mail-order to your door | In-person pickup or mail-order |
| Drug interaction checks | Limited (mail-order pharmacy only) | Comprehensive (full medication history) |
| Counts toward deductible | Usually no | Yes |
| Drug selection | Brand-name only (manufacturer's portfolio) | Brand-name and generic |
| Pharmacist relationship | No ongoing relationship | Ongoing relationship with local pharmacist |
How DirectRxGuide helps you navigate DTC drug programs
The DTC/DTP landscape is growing quickly. With 11 manufacturer platforms and dozens of eligible medications, finding the right program for your situation can be overwhelming. Each platform has its own website, its own pricing, and its own eligibility rules.
DirectRxGuide is the first independent aggregator of every active DTP program in the United States. No pharmaceutical manufacturer funds, sponsors, or influences this platform. We exist to help patients and healthcare providers compare all available options in one place.
Search by condition, drug name, or insurance status to see which programs may be available to you.
Compare prices across multiple manufacturer platforms side by side.
Understand eligibility requirements before you visit a manufacturer website.
Access updated program information daily, without needing to check each manufacturer platform individually.
Make informed decisions with no bias, no affiliate links, and no pharmaceutical industry influence.
Find your direct-to-patient options
Use our free tool to see which DTC/DTP programs match your condition and insurance status. No account required and no personal data stored.
Find My OptionsMedical disclaimer: DirectRxGuide does not provide medical advice. All content is for informational purposes only. Always consult your healthcare provider before making changes to your medications. DirectRxGuide is not a pharmacy, prescriber, or healthcare provider. Program eligibility, pricing, and availability are subject to change. Verify current details directly with the manufacturer before enrolling.